NYSE:MRK

Track all markets on TradingView - Graphs are not on time
Merck & Co., Inc. reported fourth-quarter and full-year 2025 results showing resilient performance driven by oncology and animal health, while highlighting significant progress across its late-stage pipeline.

Fourth-quarter worldwide sales rose 5% to $16.4 billion, with GAAP EPS of $1.19 and non-GAAP EPS of $2.04. For full-year 2025, Merck generated $65.0 billion in worldwide sales, up 1% year over year, supported by 7% growth in KEYTRUDA/KEYTRUDA QLEX sales to $31.7 billion, $1.4 billion in WINREVAIR sales, and strong Animal Health growth of 8%. These gains were partly offset by a sharp decline in GARDASIL/GARDASIL 9 sales.

During 2025, Merck reported positive results from 18 Phase 3 trials, expanded its pipeline through acquisitions and licensing deals, and received FDA National Priority Vouchers for key late-stage assets. Looking ahead, the company expects 2026 worldwide sales of $65.5–$67.0 billion and non-GAAP EPS of $5.00–$5.15, reflecting a one-time charge related to the Cidara Therapeutics acquisition.

Source: Merck & Co., Inc. press release
💬 🔗
Author
WS Investor 02-03-26
Merck Launches ChemiSphere App to Streamline Laboratory Data Access

Merck KGaA has launched the ChemiSphere app, a digital tool that allows scientists to instantly access product documentation and quality data by scanning 2D barcodes on lab products. Built on Merck’s M-Trust platform, the app aims to reduce manual data entry, improve data integrity, and boost efficiency in laboratory workflows.
💬 🔗
Author
WS Investor 12-22-25
Merck Reports Solid Q3 Results and Raises 2025 Outlook on Strong Oncology and New Product Performance

Merck & Co. (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, driven by continued strength in oncology and animal health. KEYTRUDA sales rose 10% to $8.1 billion, WINREVAIR surged 141% to $360 million, and CAPVAXIVE contributed $244 million in its launch quarter. GAAP EPS climbed 87% to $2.32, while non-GAAP EPS increased 64% to $2.58. The company raised its full-year sales outlook to $64.5–$65.0 billion and narrowed non-GAAP EPS guidance to $8.93–$8.98.

Merck highlighted major milestones, including FDA approval of subcutaneous KEYTRUDA QLEX, positive Phase 3 results for Enlicitide Decanoate in hypercholesterolemia, and the completion of its acquisition of Verona Pharma, strengthening its respiratory portfolio.
💬 🔗
Author
Global Finance News 10-30-25
Merck Selects Veeva Vault CRM to Support Major Launch Period

Veeva Systems (NYSE: VEEV) announced on July 21, 2025, that Merck (NYSE: MRK) has committed to adopting Veeva Vault CRM as its commercial execution platform. This move supports Merck’s entry into one of the most significant launch phases in its history, spanning multiple therapeutic areas and treatment modalities.

The partnership expands Merck’s longstanding relationship with Veeva, aiming to boost global commercial capabilities through Vault CRM’s personal and digital engagement tools and compliance-tailored features. Merck’s EVP and CIO Dave Williams highlighted the role of Vault CRM in enhancing customer success and execution.

Vault CRM is part of the broader Vault CRM Suite, designed for the life sciences industry’s complex regional and compliance needs.
💬 🔗
Author
European Investor 07-23-25

Is Merck & Co., Inc. (MRK) the Most Reliable Dividend Stock to Buy According to Hedge Funds?

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The year 2024 proved favorable for dividends, even though the Dividend Aristocrats Index lagged behind […]

(finance.yahoo.com)
💬 🔗
Author
Global Finance News 01-15-25